Omega Therapeutics, Inc. announced new preclinical data supporting the potential of OTX-2101, a c-MYC-targeting epigenomic controller (MYC-EC) being developed for the treatment of non-small cell lung cancer (NSCLC), in combination with immune checkpoint inhibitors or EGFR inhibitors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which took place in Boston, Mass., October 11 -- 15, 2023. These new data build on previous results demonstrating anti-tumor activity of OTX-2101 as a monotherapy in preclinical NSCLC models and highlight its potential ability to synergize with clinically validated strategies. These encouraging results give confidence in OTX-2101's potential as meaningful new treatment option for patients living with NSCLC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.36 USD | +0.21% | +9.51% | -21.59% |
May. 06 | Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 16 | Omega Therapeutics CFO Joshua Reed to Depart | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.59% | 130M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- OMGA Stock
- News Omega Therapeutics, Inc.
- Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC